Brought to you by 
Otsuka and Akebia enter potential $1bn deal surrounding anemia project vadadustat; deal grows; Deal Terminated
13 May 2022
Executive Summary
Otsuka Pharmaceutical Co. Ltd. and Akebia Therapeutics Inc. teamed up to further development of Akebia’s oral hypoxia-inducible factor (HIG) stabilizer vadadustat, which is in Phase III studies for anemia related to chronic kidney disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Otsuka and Akebia enter potential $1bn deal surrounding anemia project vadadustat; deal grows; Deal Terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice